Abstract
Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin HPVing HPV vaccination and hrHPV-based screening to safety extend screening intervals.
Original language | English (US) |
---|---|
Pages (from-to) | 211-219 |
Number of pages | 9 |
Journal | Salud Publica de Mexico |
Volume | 58 |
Issue number | 2 |
DOIs | |
State | Published - 2016 |
Keywords
- Cervical intraepithelial neoplasia
- Hpv
- Mass screening
- Mexico
- Vaccination
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health